<?xml version="1.0" encoding="UTF-8"?>
<ref id="CR28">
 <label>28.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Chiorean</surname>
    <given-names>EG</given-names>
   </name>
   <name>
    <surname>Sweeney</surname>
    <given-names>C</given-names>
   </name>
   <name>
    <surname>Youssoufian</surname>
    <given-names>H</given-names>
   </name>
   <name>
    <surname>Qin</surname>
    <given-names>A</given-names>
   </name>
   <name>
    <surname>Dontabhaktuni</surname>
    <given-names>A</given-names>
   </name>
   <name>
    <surname>Loizos</surname>
    <given-names>N</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>A phase I study of olaratumab, an anti-platelet-derived growth factor receptor alpha (PDGFRalpha) monoclonal antibody, in patients with advanced solid tumors</article-title>
  <source>Cancer Chemother Pharmacol</source>
  <year>2014</year>
  <volume>73</volume>
  <fpage>595</fpage>
  <lpage>604</lpage>
  <pub-id pub-id-type="doi">10.1007/s00280-014-2389-9</pub-id>
  <?supplied-pmid 24452395?>
  <pub-id pub-id-type="pmid">24452395</pub-id>
 </element-citation>
</ref>
